BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT^®

Figures & data

Table 1 Baseline Characteristics (N=500)

		n	%
Sex	Female	323	64.6
	Male	177	35.4
Diagnosis	RRMS	474	94.8
	CIS	26	5.2
Employment status	Employed	280	56.0
	Retired	61	12.2
	Keeping house	44	8.8
	Student	17	3.4
	Seeking work	21	4.2
	Other	24	4.8
	Not reported	37	7.4
Education level	Elementary	68	13.6
	Secondary	249	49.8
	College or university	144	28.8
	Apprenticeship	15	3.0
	Not reported	24	4.8
Concomitant diseases of special interest^a	Depression	70	14.0
	Anxiety	45	9.0
	Fatigue	98	19.6
	≥1 of these	155	31.0
	None of these	345	69.0
		Median (IQR)
Age, years		44 (35–52)
EDSS		1.5 (1.0–3.0)
Disease duration, months	RRMS	76.2 (30.5–144.1)
	CIS	22.7 (8.9–81.4)

Note: ^aMultiple answers per patient were possible.

Abbreviations: CIS, clinically isolated syndrome; EDSS, Expanded Disability Status Scale; RRMS, relapsing-remitting multiple sclerosis.

Figure 1 Compliance at each follow-up visit for patients with non-missing compliance data only.

Notes: (A) The median percentage of injections completed by patients using BETACONNECT^®. (B) Percentage of patients that completed ≥80% of scheduled BETACONNECT injections.

Table 2 Logistic Regression Results for Compliance and Adherence

	Multivariate OR (95% CI)	P-value
Compliance^a
Presence of concomitant diseases of special interest^b (no vs yes)	0.540 (0.263–1.107)	0.0927
MS duration at initial visit	0.994 (0.991–0.998)	0.0014
Satisfaction with myBETAapp^® (>8 vs ≤8)	10.840 (0.911–128.951)	0.0592
Adherence^c
Presence of concomitant diseases of special interest^b (no vs yes)	0.521 (0.329–0.823)	0.0052
Sex (female vs male)	0.675 (0.441–1.033)	0.0701
MS duration at initial visit	0.996 (0.994–0.999)	0.0041
SDMT at initial visit	1.017 (1.001–1.034)	0.0397

Notes: ^aDefined as the percentage of injections completed using BETACONNECT^{®. b}Fatigue, anxiety, or depression. ^cDefined as completing ≥80% of injections using BETACONNECT.

Abbreviations: OR, odds ratio; SDMT, Symbol Digit Modalities Test.

Table 3 Satisfaction with the Patient’s Previous Injection Method and BETACONNECT^® Across Visits

		N	Mean (SD)	Median (IQR)
Initial Visit	No previous BETACONNECT use	374	7.27 (2.23)	8 (6.0–9.0)
	Previous BETACONNECT use	63	7.98 (1.80)	8 (7.0–9.0)
BETACONNECT: Week 4	No previous BETACONNECT use	330	7.96 (2.12)	8.0 (7.0–10.0)
	Previous BETACONNECT use	76	8.23 (1.72)	9.0 (7.5–9.0)
BETACONNECT: Week 12	No previous BETACONNECT use	302	7.87 (2.07)	8.0 (7.0–9.0)
	Previous BETACONNECT use	78	8.21 (1.49)	8.0 (8.0–9.0)
BETACONNECT: Week 24	No previous BETACONNECT use	297	7.80 (2.17)	8.0 (6.0–9.0)
	Previous BETACONNECT use	69	8.33 (1.75)	8.5 (7.0–9.0)

Table 4 Secondary Outcome Measures

	Baseline		Week 12		Week 24
	N	Median (IQR)	N	Median (IQR)	N	Median (IQR)
FAMS total	430	135 (111–153)	344	134.4 (111–155)	338	131.5 (108–153)
HADS anxiety	438	6(3–9)	349	6 (3–9)	341	6(3–9)
HADS depression	438	4 (1–7)	351	4 (1–7)	341	4 (1–8)
CES-D	480	10 (5–19)	380	10 (5–18)	369	11 (5–19)
FSMC cognitive fatigue	471	22 (14–33)	367	23 (14–31)	363	23 (16–32)
FSMC motor fatigue	475	27 (16–36)	367	26 (17–35)	364	26 (17–35)
SDMT	433	45.0 (32–55)	282	47.0 (35–56)	318	46.5 (35–57)

Abbreviations: CES-D, Center for Epidemiological Studies Depression Scale; FAMS, Functional Assessment of Multiple Sclerosis; FSMC, Fatigue Scale for Motor and Cognitive functions; HADS, Hospital Anxiety and Depression Scale; SDMT, Symbol Digit Modalities Test.